MedTrace Logo

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

NCT00165633 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2008-12-09

No results posted yet for this study

Summary

The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.

Conditions

Interventions

DRUG

Menatetrenone

45 mg capsule, orally, three times a day, after meals.

DRUG

Menatetrenone

90 mg capsule, orally, three times a day, after meals.

DRUG

Placebo

Placebo capsule, orally, three times a day, after meals.

Sponsors & Collaborators

  • Eisai Limited

    lead INDUSTRY

Principal Investigators

  • Nozomu Koyanagi · Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2007-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165633 on ClinicalTrials.gov